Suven Life Sciences, a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, will present seven scientific posters highlighting its drug discovery and development pipeline at Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), scheduled to take place in Washington, DC, from November 14 to 18, 2026.
The presentations will cover research across several therapeutic areas, including Alzheimer’s disease, agitation, schizophrenia, narcolepsy, sleep disorders, major depressive disorder and Parkinson’s disease. The posters will showcase progress across Suven’s clinical and preclinical programmes and its work on different pharmacological mechanisms.
Commenting on the presentations, Venkat Jasti, Chairman and Managing Director, Suven Life Sciences, said, “Our participation at Neuroscience 2026 reflects the breadth and continued progress of Suven’s CNS research and development pipeline. We have a diverse portfolio of drug candidates from several important therapeutic areas, including agitation, sleep disorders, depression, schizophrenia, Parkinson’s disease and cognitive impairment. Our programmes have advanced to the different stages of development, with candidates in Phase-3 and Phase-2 clinical development, alongside promising preclinical programmes progressing towards clinical evaluation. We remain committed to advancing innovative therapies that have the potential to address significant unmet medical needs, improve outcomes for patients and create long-term value for the company.”
Ramakrishna Nirogi, President and Chief Scientific Officer, Suven Life Sciences, said, “The volume of scientific presentations at Neuroscience 2026 reflects our continued efforts in discovering and developing novel therapeutic approaches across multiple CNS targets. Our research encompasses different pharmacological mechanisms, including muscarinic M1 and M4 modulation, histamine H3 receptor inverse agonism, serotonin receptor modulation and nicotinic receptor antagonism. The presentations include findings from clinical studies of our advanced drug candidates as well as preclinical research supporting the development of our next-generation pipeline. We believe this integrated research and development approach will continue to strengthen our portfolio and support the advancement of differentiated CNS therapeutics.”
Conference attendees can visit Suven’s Exhibit Booth #423, where representatives from the scientific and business development teams of Suven Life Sciences, India, and Suven Neurosciences, USA, will be available to discuss the company’s clinical-stage pipeline, development programmes, future strategy and potential collaborations.
Suven Life Sciences Limited is focused on discovering and clinically developing innovative medicines for unmet medical needs in CNS disorders. Its portfolio includes five clinical-stage assets: Masupirdine (SUVN-502) for agitation in Alzheimer’s dementia, with a global Phase 3 study underway and enrolment completed; Samelisant (SUVNG3031) for excessive daytime sleepiness in narcolepsy, with its pivotal Phase 3 AWAKE study initiated; Ropanicant (SUVN-911) for major depressive disorder, with a Phase 2b study completed and Phase 3 in planning; Usmarapride (SUVN-D4010) for cognitive disorders, with Phase 2 in planning; and Tenaclidine (SUVN-I6107) for cognitive disorders, following completion of Phase 1. The company also has seven research projects across multiple indications and owns the intellectual property rights to its assets in all major world markets.